NCT07093489View on ClinicalTrials.gov

Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)

Not yet recruitingOBSERVATIONAL
Enrollment

11,990

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

December 31, 2027

Conditions
Mpox (Monkeypox)Mpox
Interventions
BIOLOGICAL

LC16m8

LC16m8 vaccine will be offered to all individuals aged \>1 year and meet the inclusion criteria within the catchment population. This will be done in line with the DRC government's LC16m8 vaccine roll out plan.

Trial Locations (1)

Unknown

The Institut National de la Recherche Biomédicale (INRB), Kinshasa

All Listed Sponsors
collaborator

Japan Institute for Health Security (JIHS)

UNKNOWN

collaborator

Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo

OTHER

lead

International Vaccine Institute

OTHER

NCT07093489 - Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC) | Biotech Hunter | Biotech Hunter